These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22458527)

  • 21. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib: the first biologic in the management of pancreatic cancer.
    Saif MW
    Expert Opin Pharmacother; 2008 Jun; 9(9):1595-607. PubMed ID: 18518788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
    Ciardiello F; De Vita F
    Prog Drug Res; 2005; 63():93-114. PubMed ID: 16265878
    [No Abstract]   [Full Text] [Related]  

  • 26. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
    Chang BW; Saif MW
    JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER family inhibitors in pancreatic cancer: current status and future directions.
    Berz D; Miner T; McCormack E; Safran H
    Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of erlotinib and its clinical use.
    Tang PA; Tsao MS; Moore MJ
    Expert Opin Pharmacother; 2006 Feb; 7(2):177-93. PubMed ID: 16433583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib in glioblastoma: lost in translation?
    Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME
    Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.
    Milosevic N; Kühnemuth B; Mühlberg L; Ripka S; Griesmann H; Lölkes C; Buchholz M; Aust D; Pilarsky C; Krug S; Gress T; Michl P
    Neoplasia; 2013 Dec; 15(12):1354-62. PubMed ID: 24403857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
    Tamura T
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
    Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
    Chiu JW; Wong H; Leung R; Pang R; Cheung TT; Fan ST; Poon R; Yau T
    Oncologist; 2014 Sep; 19(9):937-50. PubMed ID: 25117068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.